Key result
TAVI linked to ~42% fewer major events vs medical therapy in nonagenarians with AS.
Why the study?
Midterm outcomes in nonagenarians undergoing transcatheter aortic valve implantation (TAVI) were not well described.
Does TAVI reduce the combined outcome of all-cause death, rehospitalisation for heart failure, and stroke in nonagenarians with aortic stenosis compared to medical therapy?
Population
71,095 patients older than 90 years with aortic stenosis in France
Comparison
TAVI vs matched nonagenarians with AS treated medically and vs younger patients undergoing TAVI
Design
Cohort study using French administrative hospital discharge database
Follow-up
Median 161 days (interquartile range 13-625)
Authors
Loading...
TAVI may be feasible in selected nonagenarians; observational data leaves open optimal selection and needs prospective confirmation.
Cohort (n=71,095)
Yes
Does TAVI reduce the combined outcome of all-cause death, rehospitalisation for heart failure, and stroke in nonagenarians with aortic stenosis compared to medical therapy?
Relative Risk: 0.58
p-value: p=<0.001
TAVI in highly selected nonagenarians with aortic stenosis is associated with a lower risk of cardiovascular events compared to medical therapy, with acceptable long-term outcomes.
Deharo et al. (2020) conducted a cohort in Aortic stenosis (n=71,095). Transcatheter aortic valve implantation (TAVI) vs. Medical therapy was evaluated on Combined outcome of all-cause death, rehospitalisation for heart failure and stroke (RR 0.58, p=<0.001). In nonagenarians with aortic stenosis, TAVI was associated with a significantly lower risk of death, heart failure rehospitalization, and stroke compared to medical therapy (RR 0.58, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: